Most reports on chronic myeloid leukaemia (CML) treatment with tyrosine kinase inhibitors
(TKIs) focus on efficacy, particularly on molecular response and outcome. In contrast …

Abstract Mutations in the Bcr-Abl kinase domain may cause, or contribute to, resistance to
tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia patients. Recommendations …

Background Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than
imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in …

Purpose Bosutinib is an oral Src/Abl tyrosine kinase inhibitor. The phase III Bosutinib
Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia (BELA) trial compared …

Background Nilotinib has shown greater efficacy than imatinib in patients with newly
diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia (CML) in chronic …

Abstract The International Randomized Study of Interferon and STI571 (IRIS) demonstrated
long-term cytogenetic responses in patients with chronic-phase chronic myeloid leukemia …

Chronic myeloid leukemia (CML) is currently a disease in which patients can enjoy a near
normal life-expectancy. However, since the majority of patients will need to remain on …

The second generation BCR/ABL kinase inhibitor nilotinib is increasingly used for the
treatment of imatinib‐resistant chronic myeloid leukemia (CML). So far, nilotinib is …

Few neoplastic diseases have undergone a transformation in a relatively short period like
chronic myeloid leukemia (CML) has in the last few years. In 1960, CML was the first cancer …

Bosutinib is an oral, dual SRC/ABL 1 tyrosine kinase inhibitor for resistant/intolerant chronic
myeloid leukaemia (CML). We assessed the efficacy and safety of bosutinib 500 mg/d (n …